| 12/04/23 | 07:00:03 | 12 Apr 2023 | | £2.1 million contracts for rare disease trials |
| 21/03/23 | 07:00:02 | 21 Mar 2023 | | Block Admission Application & Exercise of Options |
| 06/02/23 | 07:00:04 | 6 Feb 2023 | | Director/PDMR Share Purchases |
| 31/01/23 | 07:00:08 | 31 Jan 2023 | | Trading Update |
| 30/01/23 | 13:14:08 | 30 Jan 2023 | | Holding(s) in Company |
| 18/01/23 | 13:14:09 | 18 Jan 2023 | | Holding(s) in Company |
| 18/01/23 | 12:22:47 | 18 Jan 2023 | | Holding(s) in Company |
| 17/01/23 | 17:54:45 | 17 Jan 2023 | | Holding(s) in Company |
| 17/01/23 | 16:06:56 | 17 Jan 2023 | | Holding(s) in Company |
| 13/01/23 | 17:09:05 | 13 Jan 2023 | | Holding(s) in Company |
| 11/01/23 | 07:00:08 | 11 Jan 2023 | | Acquisition of Winterlight Labs Inc |
| 24/11/22 | 07:00:02 | 24 Nov 2022 | | Strategic Partnership for Chinese Market Expansion |
| 19/10/22 | 07:00:06 | 19 Oct 2022 | | £1.1 million eCOA contract win |
| 12/10/22 | 07:00:04 | 12 Oct 2022 | | Acquisition of eClinicalHealth Limited |
| 20/09/22 | 07:00:08 | 20 Sept 2022 | | Interim Results |
| 01/09/22 | 07:00:05 | 1 Sept 2022 | | £2.2m neurodegenerative disease trial contract |
| 17/08/22 | 07:00:08 | 17 Aug 2022 | | Alzheimer’s Disease Validation for NeuroVocalix |
| 03/08/22 | 14:55:08 | 3 Aug 2022 | | Directorate Change |
| 28/07/22 | 07:00:14 | 28 Jul 2022 | | PTSD trials with top 10 pharma company & US DoD |
| 26/07/22 | 07:00:08 | 26 Jul 2022 | | Grant of Options |
| 22/07/22 | 11:05:51 | 22 Jul 2022 | | Second Price Monitoring Extn |
| 22/07/22 | 11:00:29 | 22 Jul 2022 | | Price Monitoring Extension |
| 22/07/22 | 07:00:03 | 22 Jul 2022 | | Director/PDMR Share Purchases |
| 21/07/22 | 07:00:08 | 21 Jul 2022 | | Trading Update and Notice of Results |
| 14/07/22 | 11:06:15 | 14 Jul 2022 | | Second Price Monitoring Extn |
| 14/07/22 | 11:00:48 | 14 Jul 2022 | | Price Monitoring Extension |
| 30/06/22 | 17:43:47 | 30 Jun 2022 | | Holding(s) in Company |
| 08/06/22 | 15:14:53 | 8 Jun 2022 | | Result of AGM |
| 16/05/22 | 16:35:11 | 16 May 2022 | | Posting of Annual Report & Notice of AGM |
| 12/04/22 | 07:00:04 | 12 Apr 2022 | | Results for the year ended 31 December 2021 |
| 06/04/22 | 07:00:07 | 6 Apr 2022 | | Senior Management Appointments |
| 31/03/22 | 07:00:10 | 31 Mar 2022 | | Notice of Results |
| 29/03/22 | 14:06:02 | 29 Mar 2022 | | Second Price Monitoring Extn |
| 29/03/22 | 14:00:58 | 29 Mar 2022 | | Price Monitoring Extension |
| 28/03/22 | 16:41:43 | 28 Mar 2022 | | Second Price Monitoring Extn |
| 28/03/22 | 16:35:59 | 28 Mar 2022 | | Price Monitoring Extension |
| 28/03/22 | 07:00:07 | 28 Mar 2022 | | £1 million contract for pivotal autoimmune trial |
| 24/03/22 | 07:00:11 | 24 Mar 2022 | | Appointment of Nominated Adviser and Joint Broker |
| 04/02/22 | 12:06:51 | 4 Feb 2022 | | Holding(s) in Company |
| 02/02/22 | 07:00:09 | 2 Feb 2022 | | £2.1 million contract |
| 27/01/22 | 07:00:06 | 27 Jan 2022 | | Trading Update |
| 10/01/22 | 07:00:08 | 10 Jan 2022 | | New Major Pharma Client for Schizophrenia Trials |
| 16/12/21 | 07:00:05 | 16 Dec 2021 | | Electronic Clinical Outcomes Assessment Contract |
| 09/12/21 | 07:00:06 | 9 Dec 2021 | | £1.0m Schizophrenia clinical trial contract |
| 22/11/21 | 11:50:04 | 22 Nov 2021 | | Holding(s) in Company |
| 16/11/21 | 07:00:12 | 16 Nov 2021 | | Grant of Options |
| 02/11/21 | 07:00:05 | 2 Nov 2021 | | Directorate Change |
| 26/10/21 | 07:00:04 | 26 Oct 2021 | | Contract for pivotal schizophrenia clinical trial |
| 06/10/21 | 10:06:56 | 6 Oct 2021 | | Holding(s) in Company |
| 21/09/21 | 07:00:07 | 21 Sept 2021 | | Interim Results |
